- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
- Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
- Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
More ▼
Key statistics
On Tuesday, Ligand Pharmaceuticals Inc (LGND:NMQ) closed at 85.98, -9.08% below its 52-week high of 94.57, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 85.60 |
---|---|
High | 86.86 |
Low | 84.13 |
Bid | 83.00 |
Offer | 93.45 |
Previous close | 85.98 |
Average volume | 130.35k |
---|---|
Shares outstanding | 17.96m |
Free float | 17.55m |
P/E (TTM) | 16.43 |
Market cap | 1.54bn USD |
EPS (TTM) | 5.23 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼